AMACR, which has been reported to regulate the metabolism of fatty acid, cholalic acid [51] and closely associated with the differential diagnosis of prostatic cancer [52], was down regulated by over 2.8 folds in R/M≤6months group compared to the NR/M group, but up-regulated more than 2.2 folds in R/M6-12months group compared to the NR/M group. This evidence concerns the gene AMACR and prostate cancer.